King's College London

Research portal

Laryngeal and Pharyngeal Squamous Cell Carcinoma after Antireflux Surgery in the 5 Nordic Countries

Research output: Contribution to journalArticlepeer-review

Manar Yanes, Giola Santoni, John Maret-Ouda, Eivind Ness-Jensen, Martti Färkkilä, Elsebeth Lynge, Eero Pukkala, Pål Romundstad, Laufey Tryggvadóttir, My Von Euler-Chelpin, Jesper Lagergren

Original languageEnglish
Pages (from-to)E79-E85
JournalAnnals of Surgery
Volume276
Issue number2
DOIs
Published1 Aug 2022

Bibliographical note

Funding Information: Funding: This work was supported by the Nordic Cancer Union (grant number 186058), Swedish Cancer Society (grant number 180684), and Swedish Research Council (grant number 340–2013–5478). Jesper Lagergren was supported by the United European Gastroenterology Research Prize and the Distinguished Professor Award at Karolinska Institutet. Publisher Copyright: © 2022 Lippincott Williams and Wilkins. All rights reserved.

King's Authors

Abstract

Objective: The aim of this study was to clarify whether antireflux surgery prevents laryngeal and pharyngeal squamous cell carcinoma. Summary Background Data: Gastroesophageal reflux disease (GERD) seems to increase the risk of laryngeal and pharyngeal squamous cell carcinoma. Methods: All-Nordic (Denmark, Finland, Iceland, Norway, and Sweden) population-based cohort study of adults with documented GERD in 1980 to 2014. First, cancer risk after antireflux surgery was compared to the expected risk in the corresponding background population by calculating standardized incidence ratios (SIRs) with 95% confidence intervals (CIs). Second, cancer risk among antireflux surgery patients was compared to nonoperated GERD patients using multivariable Cox regression, providing hazard ratios (HR) with 95% CIs, adjusted for sex, age, calendar period, and diagnoses related to tobacco smoking, obesity, and alcohol overconsumption. Results: Among 814,230 GERD patients, 47,016 (5.8%) underwent antireflux surgery. The overall SIRs and HRs of the combined outcome laryngeal or pharyngeal squamous cell carcinoma (n=39) were decreased after antireflux surgery [SIR=0.62 (95% CI 0.44-0.85) and HR=0.55 (95% CI 0.38-0.80)]. The point estimates were further decreased >10 years after antireflux surgery [SIR=0.48 (95% CI 0.26-0.80) and HR=0.47 (95% CI 0.26-0.85)]. The risk estimates of laryngeal squamous cell carcinoma were particularly decreased >10 years after antireflux surgery [SIR=0.28 (95% CI 0.08-0.72) and HR=0.23 (95% CI 0.08-0.69)], whereas no such decrease over time after surgery was found for pharyngeal squamous cell carcinoma. Analyses of patients with severe GERD (reflux esophagitis or Barrett esophagus) showed similar results. Conclusion: Antireflux surgery may decrease the risk of laryngeal squamous cell carcinoma and possibly also of pharyngeal squamous cell carcinoma.

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454